Other Plasma Cell Disorders Multiple Myeloma Causes and Risk Factors Multiple Myeloma Symptoms Multiple Myeloma Diagnosis 8 min read Multiple myeloma, also known as Kahler's disease, is a type of blood cancer. There's no cure, but treatments can slow its spread and sometimes make symptoms go ...
Introduction: Multiple myeloma (MM) is a rare, heterogenous, progressive plasma cell disorder that has one of the longest times to diagnosis of all cancers. Patients commonly present with non-specific symptoms, including bone pain or fractures, recurrent infections, fatigue or renal failure alongside...
This is a common test used to diagnose multiple myeloma. Your doctor will remove a piece of bone marrow or take a sample of cells from your body and check it in a lab under a microscope for signs of cancer. These types ofbiopsiesare most often used to help diagnose multiple myeloma: Bo...
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers...
An x-ray of your whole body can be done to see how many bones could be damaged by the myeloma. Biopsy: Your doctor removes tissue to look for cancer cells. A biopsy is the only sure way to know whether myeloma cells are in your bone marrow. Before the sample is taken, local ...
For patients newly diagnosed with multiple myeloma in Oregon's Willamette Valley, our team of blood cancer specialists can walk you through what to expect
X-rays: You may have x-rays to check for broken or thinning bones.An x-ray of your whole body can be done to see how many bones could be damaged by the myeloma. Biopsy: Your doctor removes tissue to look for cancer cells. A biopsy is the only sure way to know whether myeloma cel...
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer View More Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials View More Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluati...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eli...
Multiple myeloma accounts for 1.6% of all cancer cases and approximately 10% of hematologic malignancies in the United States. In 2015, an estimated 28,850 new cases of multiple myeloma were diagnosed in the United States, and the disease caused more than 11,000 deaths. Patients older than 65...